Structure Therapeutics (GPCR) EBT (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly EBT of -$75.8 million for Q1 2026, down 62.14% year-over-year from -$200.2 million in Q1 2025, and down 142.75% quarter-over-quarter from $177.3 million in Q4 2025.
Structure Therapeutics (GPCR) EBT (2022 - 2026) Analysis & Trends
Structure Therapeutics' EBT history runs 5 years deep, the most recent figure standing at -$75.8 million for Q1 2026.
- In Q1 2026, EBT fell 62.14% year-over-year to -$75.8 million; the TTM figure through Mar 2026 stood at -$25.7 million (up 14.02% YoY), while the FY2025 annual figure was $3.4 million, up 137.22% from the prior year.
- EBT for Q1 2026 stood at -$75.8 million, down from $177.3 million in the prior quarter.
- The five-year high for EBT was $177.3 million in Q4 2025, with the low at -$75.8 million in Q1 2026.
- The 5-year median for EBT is -$23.2 million (2023), against an average of -$5.8 million.
- Peak annual rise in EBT reached 130.9% in 2025, while the deepest fall reached 136.8% in 2025.
- Structure Therapeutics' EBT stood at $32.2 million in 2022, then jumped by 71.04% to $55.1 million in 2023, then jumped by 39.37% to $76.8 million in 2024, then surged by 130.9% to $177.3 million in 2025, then plunged by 142.75% to -$75.8 million in 2026.
- Business Quant data shows GPCR's EBT at -$75.8 million in Q1 2026, $177.3 million in Q4 2025, and -$65.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -105.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -105.93 Mn |
| Mar 31, 2026 | -75.78 Mn |
| Dec 31, 2025 | 177.25 Mn |
| Sep 30, 2025 | -65.60 Mn |
| Jun 30, 2025 | -61.52 Mn |
| Mar 31, 2025 | -46.74 Mn |
| Dec 31, 2024 | 76.76 Mn |
| Sep 30, 2024 | -33.89 Mn |
| Jun 30, 2024 | -25.98 Mn |
| Mar 31, 2024 | -26.01 Mn |
| Dec 31, 2023 | 55.08 Mn |
| Sep 30, 2023 | -23.46 Mn |
| Jun 30, 2023 | -23.16 Mn |
| Mar 31, 2023 | -17.95 Mn |
| Dec 31, 2022 | 32.20 Mn |
| Sep 30, 2022 | -12.34 Mn |
| Jun 30, 2022 | -13.88 Mn |
| Mar 31, 2022 | -13.02 Mn |